Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis.

[1]  J. Bouma,et al.  Role of an early second-look laparotomy in ovarian cancer. , 1989, Gynecologic oncology.

[2]  W. Watring,et al.  Second-look procedures in ovarian cancer patients receiving six vs. nine courses of platinum, adriamycin, cytoxan (PAC) chemotherapy: the SCPMG experience 1982-1985. , 1989, Gynecologic oncology.

[3]  R. Figlin,et al.  Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the functional living index—cancer , 1988, Cancer.

[4]  M. Tattersall,et al.  Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.

[5]  J. Neijt,et al.  Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Gelber,et al.  A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Yordan,et al.  A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study , 1986, Cancer.

[8]  R. Scully,et al.  Medical progress: common epithelial cancer of the ovary (second of two parts) , 1985 .

[9]  J. Neijt,et al.  RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA , 1984, The Lancet.

[10]  R. Olshen,et al.  Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. , 1983, Cancer research.

[11]  T. Fleming,et al.  Cyclophosphamide plus cis-Platinum in Combination: Treatment Program for Stage III or IV Ovarian Carcinoma , 1982, Obstetrics and gynecology.

[12]  L. Burnett,et al.  Advanced Ovarian Cancer: Brief Intensive Combination Chemotherapy and Second-Look Operation , 1981, Obstetrics and gynecology.

[13]  R. Fisher,et al.  Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. , 1978, The New England journal of medicine.

[14]  C. Wilson,et al.  FENFLURAMINE AND DREAMING , 1974 .

[15]  P. Skarbanek.  Letter: Body-temperature and myasthenia. , 1974, Lancet.

[16]  P Glasziou,et al.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Scully,et al.  Common epithelial cancer of the ovary: second of two parts , 1985 .